Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam
· Delayed Price · Currency is VND 20,400
0.00 (0.00%)
At close: Mar 31, 2026
HNX:MED Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 366,830 | 443,136 | 402,741 | 401,051 | 343,951 | Upgrade
|
| Revenue Growth (YoY) | -17.22% | 10.03% | 0.42% | 16.60% | -34.03% | Upgrade
|
| Cost of Revenue | 281,043 | 350,574 | 319,663 | 321,750 | 275,877 | Upgrade
|
| Gross Profit | 85,787 | 92,561 | 83,078 | 79,301 | 68,074 | Upgrade
|
| Selling, General & Admin | 63,361 | 70,368 | 68,897 | 70,666 | 59,184 | Upgrade
|
| Operating Expenses | 63,361 | 70,368 | 68,897 | 70,666 | 59,184 | Upgrade
|
| Operating Income | 22,426 | 22,193 | 14,181 | 8,634 | 8,890 | Upgrade
|
| Interest Expense | -2,316 | -3,787 | -5,394 | -5,004 | -3,619 | Upgrade
|
| Interest & Investment Income | 490.9 | 790.11 | 6,580 | 5,811 | 4,790 | Upgrade
|
| Currency Exchange Gain (Loss) | -478.97 | -690.35 | -45.37 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 537.65 | 928.43 | -212.84 | -774.96 | -4,533 | Upgrade
|
| EBT Excluding Unusual Items | 20,659 | 19,434 | 15,109 | 8,666 | 5,528 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -16.21 | -185.78 | - | - | Upgrade
|
| Pretax Income | 20,659 | 19,418 | 14,923 | 8,666 | 5,528 | Upgrade
|
| Income Tax Expense | 4,826 | 4,171 | 3,179 | 2,300 | 1,781 | Upgrade
|
| Net Income | 15,833 | 15,247 | 11,744 | 6,366 | 3,747 | Upgrade
|
| Net Income to Common | 15,833 | 15,247 | 11,744 | 6,366 | 3,747 | Upgrade
|
| Net Income Growth | 3.85% | 29.83% | 84.49% | 69.88% | -84.66% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 12 | 9 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 12 | 9 | 6 | Upgrade
|
| Shares Change (YoY) | - | - | 32.18% | 49.59% | -0.05% | Upgrade
|
| EPS (Basic) | 1275.86 | 1228.59 | 946.32 | 678.00 | 597.00 | Upgrade
|
| EPS (Diluted) | 1275.86 | 1228.59 | 946.32 | 678.00 | 597.00 | Upgrade
|
| EPS Growth | 3.85% | 29.83% | 39.58% | 13.57% | -84.65% | Upgrade
|
| Free Cash Flow | -15,144 | 37,674 | -84,502 | -91,039 | 7,746 | Upgrade
|
| Free Cash Flow Per Share | -1220.28 | 3035.74 | -6809.19 | -9696.32 | 1234.13 | Upgrade
|
| Dividend Per Share | - | - | 900.000 | 500.000 | 250.000 | Upgrade
|
| Dividend Growth | - | - | 80.00% | 100.00% | - | Upgrade
|
| Gross Margin | 23.39% | 20.89% | 20.63% | 19.77% | 19.79% | Upgrade
|
| Operating Margin | 6.11% | 5.01% | 3.52% | 2.15% | 2.58% | Upgrade
|
| Profit Margin | 4.32% | 3.44% | 2.92% | 1.59% | 1.09% | Upgrade
|
| Free Cash Flow Margin | -4.13% | 8.50% | -20.98% | -22.70% | 2.25% | Upgrade
|
| EBITDA | 29,594 | 30,109 | 22,625 | 18,654 | 18,426 | Upgrade
|
| EBITDA Margin | 8.07% | 6.79% | 5.62% | 4.65% | 5.36% | Upgrade
|
| D&A For EBITDA | 7,169 | 7,916 | 8,444 | 10,020 | 9,536 | Upgrade
|
| EBIT | 22,426 | 22,193 | 14,181 | 8,634 | 8,890 | Upgrade
|
| EBIT Margin | 6.11% | 5.01% | 3.52% | 2.15% | 2.58% | Upgrade
|
| Effective Tax Rate | 23.36% | 21.48% | 21.30% | 26.55% | 32.22% | Upgrade
|
| Revenue as Reported | 366,830 | 443,136 | 402,741 | 401,051 | 343,951 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.